PRINTER'S NO. 3826
THE GENERAL ASSEMBLY OF PENNSYLVANIA
HOUSE BILL
No.
2330
Session of
2015
INTRODUCED BY KAUFER, DRISCOLL, HARHART, BOBACK, TOOHIL,
D. PARKER, TAYLOR, RADER, COOK-ARTIS, RAPP, DAVIS, MURT,
BAKER, GINGRICH AND KAUFFMAN, SEPTEMBER 9, 2016
REFERRED TO COMMITTEE ON PROFESSIONAL LICENSURE,
SEPTEMBER 9, 2016
AN ACT
Amending the act of December 20, 1985 (P.L.457, No.112),
entitled "An act relating to the right to practice medicine
and surgery and the right to practice medically related acts;
reestablishing the State Board of Medical Education and
Licensure as the State Board of Medicine and providing for
its composition, powers and duties; providing for the
issuance of licenses and certificates and the suspension and
revocation of licenses and certificates; provided penalties;
and making repeals," providing for provision of buprenorphine
and legend drugs and further providing for reasons for
refusal, revocation, suspension or other corrective actions
against a licensee or certificate holder.
The General Assembly of the Commonwealth of Pennsylvania
hereby enacts as follows:
Section 1. The act of December 20, 1985 (P.L.457, No.112),
known as the Medical Practice Act of 1985, is amended by adding
a section to read:
Section 36.3. Provision of buprenorphine and legend drugs.
(a) Duty.--The board shall promulgate guidelines restricting
when buprenorphine is provided to a patient for the purpose of
treating drug dependence or addiction. The promulgated
guidelines shall require that the provision of buprenorphine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
may only occur in conjunction with an opioid treatment program
that meets all of the following:
(1) Is the subject of a current and valid certification
from the Substance Abuse and Mental Health Services
Administration of the United States Department of Health and
Human Services.
(2) Is comprehensive and includes counseling and
behavioral therapy.
(b) Legend drugs.--The board may adopt promulgated
guidelines that establish standards and procedures for
prescribing a legend drug to treat opioid dependence or
addiction. The board may limit the application of the guidelines
to treatment provided through an office-based practice or other
practice type or location specified by the board.
Section 2. Section 41 of the act is amended by adding a
paragraph to read:
Section 41. Reasons for refusal, revocation, suspension or
other corrective actions against a licensee or
certificate holder.
The board shall have authority to impose disciplinary or
corrective measures on a board-regulated practitioner for any or
all of the following reasons:
* * *
(12) Violating section 36.3(a). The board shall
promulgate guidelines providing for specific periods of
license suspension or revocation for dispensing, injecting,
implanting or prescribing buprenorphine in violation of
section 36.3.
Section 3. This act shall take effect in 60 days.
20160HB2330PN3826 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29